168 related articles for article (PubMed ID: 37990599)
1. Designing drugs and chemical probes with the dualsteric approach.
Zha J; He J; Wu C; Zhang M; Liu X; Zhang J
Chem Soc Rev; 2023 Dec; 52(24):8651-8677. PubMed ID: 37990599
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands.
Gado F; Ferrisi R; Polini B; Mohamed KA; Ricardi C; Lucarini E; Carpi S; Domenichini F; Stevenson LA; Rapposelli S; Saccomanni G; Nieri P; Ortore G; Pertwee RG; Ghelardini C; Di Cesare Mannelli L; Chiellini G; Laprairie RB; Manera C
J Med Chem; 2022 Jul; 65(14):9918-9938. PubMed ID: 35849804
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.
Reinecke BA; Wang H; Zhang Y
Curr Top Med Chem; 2019; 19(26):2378-2392. PubMed ID: 31833462
[TBL] [Abstract][Full Text] [Related]
4. Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors.
Mohr K; Schmitz J; Schrage R; Tränkle C; Holzgrabe U
Angew Chem Int Ed Engl; 2013 Jan; 52(2):508-16. PubMed ID: 23225228
[TBL] [Abstract][Full Text] [Related]
5. Nanobody-Mediated Dualsteric Engagement of the Angiotensin Receptor Broadens Biased Ligand Pharmacology.
Braga Emidio N; Small BM; Keller AR; Cheloha RW; Wingler LM
Mol Pharmacol; 2024 Feb; 105(3):260-271. PubMed ID: 38164609
[TBL] [Abstract][Full Text] [Related]
6. Rational design of dualsteric GPCR ligands: quests and promise.
Mohr K; Tränkle C; Kostenis E; Barocelli E; De Amici M; Holzgrabe U
Br J Pharmacol; 2010 Mar; 159(5):997-1008. PubMed ID: 20136835
[TBL] [Abstract][Full Text] [Related]
7. New Insights into Bitopic Orthosteric/Allosteric Ligands of Cannabinoid Receptor Type 2.
Ferrisi R; Polini B; Ricardi C; Gado F; Mohamed KA; Baron G; Faiella S; Poli G; Rapposelli S; Saccomanni G; Aldini G; Chiellini G; Laprairie RB; Manera C; Ortore G
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768458
[TBL] [Abstract][Full Text] [Related]
8. Dopamine D2 Receptors Dimers: How can we Pharmacologically Target Them?
Carli M; Kolachalam S; Aringhieri S; Rossi M; Giovannini L; Maggio R; Scarselli M
Curr Neuropharmacol; 2018 Jan; 16(2):222-230. PubMed ID: 28521704
[TBL] [Abstract][Full Text] [Related]
9. The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors.
Valant C; Robert Lane J; Sexton PM; Christopoulos A
Annu Rev Pharmacol Toxicol; 2012; 52():153-78. PubMed ID: 21910627
[TBL] [Abstract][Full Text] [Related]
10. Allosteric modulators targeting CNS muscarinic receptors.
Bock A; Schrage R; Mohr K
Neuropharmacology; 2018 Jul; 136(Pt C):427-437. PubMed ID: 28935216
[TBL] [Abstract][Full Text] [Related]
11. Dualsteric muscarinic antagonists--orthosteric binding pose controls allosteric subtype selectivity.
Schmitz J; van der Mey D; Bermudez M; Klöckner J; Schrage R; Kostenis E; Tränkle C; Wolber G; Mohr K; Holzgrabe U
J Med Chem; 2014 Aug; 57(15):6739-50. PubMed ID: 25051097
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel orthosteric-allosteric ligands of the cannabinoid receptor type 2 (CB
Ferrisi R; Gado F; Polini B; Ricardi C; Mohamed KA; Stevenson LA; Ortore G; Rapposelli S; Saccomanni G; Pertwee RG; Laprairie RB; Manera C; Chiellini G
Front Chem; 2022; 10():984069. PubMed ID: 36238097
[TBL] [Abstract][Full Text] [Related]
13. Computational Advances for the Development of Allosteric Modulators and Bitopic Ligands in G Protein-Coupled Receptors.
Feng Z; Hu G; Ma S; Xie XQ
AAPS J; 2015 Sep; 17(5):1080-95. PubMed ID: 25940084
[TBL] [Abstract][Full Text] [Related]
14. Bivalent and bitopic ligands of the opioid receptors: The prospects of a dual approach.
Hovah ME; Holzgrabe U
Med Res Rev; 2024 May; ():. PubMed ID: 38751227
[TBL] [Abstract][Full Text] [Related]
15. Structural Characteristics of the Allosteric Binding Site Represent a Key to Subtype Selective Modulators of Muscarinic Acetylcholine Receptors.
Bermudez M; Rakers C; Wolber G
Mol Inform; 2015 Aug; 34(8):526-30. PubMed ID: 27490498
[TBL] [Abstract][Full Text] [Related]
16. Exploration of the orthosteric/allosteric interface in human M1 muscarinic receptors by bitopic fluorescent ligands.
Daval SB; Kellenberger E; Bonnet D; Utard V; Galzi JL; Ilien B
Mol Pharmacol; 2013 Jul; 84(1):71-85. PubMed ID: 23604140
[TBL] [Abstract][Full Text] [Related]
17. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand.
Valant C; Gregory KJ; Hall NE; Scammells PJ; Lew MJ; Sexton PM; Christopoulos A
J Biol Chem; 2008 Oct; 283(43):29312-21. PubMed ID: 18723515
[TBL] [Abstract][Full Text] [Related]
18. Analysis of equilibrium binding of an orthosteric tracer and two allosteric modulators.
Jakubík J; Randáková A; El-Fakahany EE; Doležal V
PLoS One; 2019; 14(3):e0214255. PubMed ID: 30917186
[TBL] [Abstract][Full Text] [Related]
19. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs.
Valant C; Sexton PM; Christopoulos A
Mol Interv; 2009 Jun; 9(3):125-35. PubMed ID: 19592673
[TBL] [Abstract][Full Text] [Related]
20. Dualsteric GPCR targeting and functional selectivity: the paradigmatic M(2) muscarinic acetylcholine receptor.
Bock A; Mohr K
Drug Discov Today Technol; 2013; 10(2):e245-52. PubMed ID: 24050275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
